• 1
    Steinmann RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137: 11421162.
  • 2
    Romani N, Schuler G. The immunologic properties of epidermal Langerhans cells as a part of the dendritic cell system. Semin Immunopathol 1992; 13: 265279.
  • 3
    Kersall BL, Strober W. Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch. J Exp Med 1996; 183: 237247.
  • 4
    Lu L, Woo J, Rao AS, et al. Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med 1994; 179: 18231834.
  • 5
    Aager R, Crowley MT, Witmer-Pack MD. The surface of dendritic cells in the mouse as studied with monoclonal antibodies. Int Rev Immunol 1990; 6: 89101.
  • 6
    Steinman RM, Inaba K. Stimulation of the primary mixed leukocyte reaction. CRC Crit Rev Immunol 1985; 5: 331338.
  • 7
    Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271296.
  • 8
    Caux C, Vanbervliet B, Massacrier C, et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 1994; 180: 18411847.
  • 9
    Inaba K, Witmer-Pack M, Inaba M, et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 1994; 180: 18491860.
  • 10
    Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 11091118.
  • 11
    Koch F, Trockenbacher B, Schuler G, et al. Antigen processing capacity of dendritic cells from mice of different MHC backgrounds: down-regulation upon culture and evidence for heterogeneity of dendritic cell populations. Adv Exp Med 1995; 378: 203206.
  • 12
    Fagnoni FF, Takamizawa M, Godfrey WR, et al. Role of B70/B7-2 in CD4+ T immune responses induced by dendritic cells. Immunology 1995; 85: 467474.
  • 13
    Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 5258.
  • 14
    Koch F, Heufler C, Kampgen E, et al. Tumor necrosis factor α maintains the viability of murine epidermal Langerhans cells in culture, but in contrast to granulocyte/macrophage colony-stimulating factor, without inducing their functional maturation. J Exp Med 1990; 171: 159171.
  • 15
    Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176: 16931702.
  • 16
    Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 8393.
  • 17
    Caux C, Vanbervliet B, Massacrier C, et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNFα. J Exp Med 1996; 184: 695706.
  • 18
    Zorina T, Mayordomo JI, Watkins S, et al. Culture of dendritic cells from murine bone marrow supplemented with GM-CSF and TNF-alpha. J Immunother 1994; 16:247
  • 19
    Santiago-Schwarz F, Rappa DA, Laky K, et al. Stem cell factor augments tumor necrosis factor-granulocyte-macrophage colony-stimulating factor-mediated dendritic cell hematopoiesis. Stem Cells 1995; 13: 186197.
  • 20
    Siena S, Di Nicola M, Mortarini R, et al. Efficient ex vivo generation of functional dendritic cells (DCs) utilizable for tumor vaccination from blood cell transplants (BCT) in cancer patients. Proc Am Soc Clin Oncol 1996; 15:554
  • 21
    Shurin MR, Pandharipande PP, Sikora SS, et al. Characterization of dendritic cells obtained from mice treated with flt3 ligand and IL-12. Fourth International Symposium on Dendritic Cells in Fundamental and Clinical Immunology. Venice (Italy), October 5-10, 1996.
  • 22
    Aichele P, Brduscha-Riem K, Zinkernagel RM, et al. T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 1995; 182: 261266.
  • 23
    Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995; 182: 255260.
  • 24
    Mizoguchi H, O'Shea JJ, Longo DL, et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258: 17951798.
  • 25
    Huang AYC, Golumbeck P, Ahmadzadeh M, et al. The role of bone marrow-derived cells in presenting class I-restricted tumor antigens. Science 1994; 264: 961965.
  • 26
    Zeid NA, Multer HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993; 25: 338343.
  • 27
    Gallo O, Libonati GA, Gallina E, et al. Langerhans cells related to prognosis in patients with laryngeal carcinoma. Arch Otorhinolaryngol 1991; 117: 10071010.
  • 28
    Giannini A, Bianchi S, Messerini L, et al. Prognostic significance of accessory cells and lymphocytes in nasopharyngeal carcinoma. Pathol Res Pract 1991; 187: 496502.
  • 29
    Becker Y. Dendritic cell activity against primary tumors: an overview. In Vivo 1993; 7: 187191.
  • 30
    Qin Z, Noffz G, Mohaupt M, et al. Interleukin 10 prevents dendritic cell infiltration and vaccination with granulocyte-macrophage-colony-stimulating-factor gene modified tumor cells. J Mol Med 1996; 74:B9.
  • 31
    Grabbe S, Beissert S, Schwartz T, et al. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 1995; 16: 116120.
  • 32
    Pardoll D. Tumour antigens: a new look for the 1990s. Nature 1994; 369: 357358.
  • 33
    Storkus WJ, Lotze MT. Biology of tumor antigens: tumor antigens recognized by immune cells. In: DeVitaVT, HellmanS, RosenbergSA, eds. Biologic Therapy of Cancer, 2nd edition. Philadelphia: J.B. Lippincott Company, 1995: 6477
  • 34
    Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Medicine 1995; 1: 12971302.
  • 35
    Feltkamp MCW, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papilloma virus type 16-transformed cells. Eur J Immunol 1993; 23: 22422249.
  • 36
    Falo LD, Kovacsovics-Bankowski M, Thompson K, et al. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nature Medicine 1995; 1: 649653.
  • 37
    Mandelboim O, Berke G, Fridkin M, et al. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 1994; 369: 6771.
  • 38
    Noguchi Y, Chen YT, Old LJ. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA 1994; 91: 31713175.
  • 39
    Mayordomo JI, Loftus DJ, Sakamoto H, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183: 13571365.
  • 40
    Celluzzi C, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996; 183: 283287.
  • 41
    Gyure LA, Barfoot R, Denham S, et al. Immunity to a syngeneic sarcoma induced in rats by syngeneic lymph cells exposed to the tumour either in vivo or in vitro. Br J Cancer 1987; 55: 1720.
  • 42
    Knight SC, Hunt R, Dore C, et al. Influence of dendritic cells on tumor growth. Proc Natl Acad Sci USA 1985; 82: 44954497.
  • 43
    Caux C, Liu Y-L, Banchereau J. Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today 1995; 16: 24.
  • 44
    Grabbe S, Bruvers S, Gallo RL, et al. Tumor antigen presentation by murine epidermal cells. J Immunol 1991; 146: 36563661.
  • 45
    Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994; 24: 605610.
  • 46
    Castelli C, Storkus WJ, Maeurer MJ, et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995; 181: 363368.
  • 47
    Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264: 716719.
  • 48
    Storkus WJ, Zeh HJ III, Salter RD, et al. Identification of T cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 1993; 14: 94103.
  • 49
    Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 8797.
  • 50
    Boczkowski D, Nair SK, Snyder D, et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465472.
  • 51
    Bellone M, Iezzi G, Manfredi AA, et al. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur J Immunol 1994; 24: 26912698.
  • 52
    Pan Z-K, Ikonomidis G, Lazenby A, et al. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nature Medicine 1995; 1: 471477.
  • 53
    Hsu FJ, Benike C, Fagnoni F, et al. A clinical trial of antigen-pulsed dendritic cells in the treatment of patients with B-cell lymphoma. Proc Am Soc Clin Oncol 1996; 15:419
  • 54
    Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327: 12091215.
  • 55
    Storkus, WJ, Mayordomo JI, DeLeo A, et al. Dendritic cells pulsed with tumor epitopes elicit potent antitumor CTL in vitro and in vivo. Meeting of the International Association of Immunology, 1995: 3493a.
  • 56
    Bakker ABH, Marland G, de Boer AJ, et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995; 55: 53305334.
  • 57
    Koch F, Stanzl U, Jennewein P, et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 1996; 184: 741746.
  • 58
    Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747752.
  • 59
    Storkus WJ, Mayordomo JI. Gene-modified dendritic cells as biologic adjuvants for cancer immunotherapy. J Mol Med 1996; 74:B11.